Nanhua Bio Medicine Co Ltd

Nanhua Bio-medicine released its 2026 interim report, with net profit attributable to the parent company of 5.99 million yuan, an increase of 9.48 million yuan compared with the same period last year, turning from a loss to a profit. The company's total operating revenue was 296 million yuan, up 473.56 percent year on year. Net cash flow from operating activities was negative 5.96 million yuan. The latest asset-liability ratio was 59.28 percent, down 4.41 percentage points from the previous quarter. The company's latest gross margin was 10.01 percent, and its latest return on equity was 2.21 percent, up 3.70 percentage points from a year earlier. Diluted earnings per share were 0.02 yuan, an increase of 0.03 yuan from the same period last year, marking three consecutive years of growth.